U.S. patent application number 14/531352 was filed with the patent office on 2015-06-04 for ceftolozane-tazobactam pharmaceutical compositions.
This patent application is currently assigned to CALIXA THERAPEUTICS, INC.. The applicant listed for this patent is Calixa Therapeutics, Inc.. Invention is credited to Nicole Miller Damour, Giuseppe Alessandro Donadelli, Giovanni Fogliato, Chun Jiang, Dario Resemini, Joseph Terracciano.
Application Number | 20150150883 14/531352 |
Document ID | / |
Family ID | 51522651 |
Filed Date | 2015-06-04 |
United States Patent
Application |
20150150883 |
Kind Code |
A1 |
Jiang; Chun ; et
al. |
June 4, 2015 |
CEFTOLOZANE-TAZOBACTAM PHARMACEUTICAL COMPOSITIONS
Abstract
Pharmaceutical compositions can include ceftolozane lyophilized
in the absence of tazobactam.
Inventors: |
Jiang; Chun; (Hillsborough,
CA) ; Terracciano; Joseph; (Concord, MA) ;
Damour; Nicole Miller; (Belmont, MA) ; Fogliato;
Giovanni; (Barzana (BG), IT) ; Donadelli; Giuseppe
Alessandro; (Casalpusterlengo (Lodi), IT) ; Resemini;
Dario; (Milan, IT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Calixa Therapeutics, Inc. |
Lexington |
MA |
US |
|
|
Assignee: |
CALIXA THERAPEUTICS, INC.
Lexington
MA
|
Family ID: |
51522651 |
Appl. No.: |
14/531352 |
Filed: |
November 3, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14214212 |
Mar 14, 2014 |
|
|
|
14531352 |
|
|
|
|
61792092 |
Mar 15, 2013 |
|
|
|
61793007 |
Mar 15, 2013 |
|
|
|
Current U.S.
Class: |
514/192 |
Current CPC
Class: |
A61K 9/19 20130101; A61K
31/43 20130101; A61K 47/183 20130101; A61K 47/02 20130101; A61K
31/431 20130101; A61K 31/546 20130101; A61K 2300/00 20130101; A61K
2300/00 20130101; A61K 2300/00 20130101; A61K 31/198 20130101; A61K
31/545 20130101; A61K 47/12 20130101; A61K 31/198 20130101; A61K
31/431 20130101; A61K 31/546 20130101 |
International
Class: |
A61K 31/546 20060101
A61K031/546; A61K 31/431 20060101 A61K031/431 |
Claims
1. A unit dosage form of a pharmaceutical composition formulated
for parenteral administration for the treatment of a complicated
intra-abdominal infection or a complicated urinary tract infection,
the pharmaceutical composition comprising ceftolozane and
tazobactam in a ratio of 1,000 mg ceftolozane active per 500 mg of
tazobactam active, the pharmaceutical composition obtained by a
process comprising the steps of: a. lyophilizing a first aqueous
solution in the absence of tazobactam, the first aqueous solution
comprising ceftolozane, at a pH of 6-7 prior to lyophilization to
obtain a first lyophilized ceftolozane composition; b. lyophilizing
a second solution comprising tazobactam in the absence of
ceftolozane to form a second lyophilized tazobactam composition;
and c. blending the first lyophilized ceftolozane composition and
the second lyophilized tazobactam composition to obtain the
antibacterial composition.
2. The unit dosage form of claim 1, wherein the tazobactam in the
second solution is tazobactam acid, and wherein the tazobactam acid
in the second solution is lyophilized in the presence of sodium
bicarbonate to form the second lyophilized tazobactam solution.
3. The unit dosage form of claim 1, comprising a total of 1,000 mg
of ceftolozane active.
4. The unit dosage form of claim 3, comprising a total of 500 mg of
tazobactam active.
5. The unit dosage form of claim 1, wherein the unit dosage form is
obtained by a process further comprising dissolving the
antibacterial composition comprising the ceftolozane and the
tazobactam with a pharmaceutically acceptable carrier to obtain the
pharmaceutical composition in a formulation for intravenous
administration.
6. The unit dosage form of claim 5, wherein the ceftolozane
comprises ceftolozane sulfate.
7. The unit dosage form of claim 5, wherein the tazobactam
comprises tazobactam sodium.
8. The unit dosage form of claim 1, wherein the unit dosage form is
a vial or a bag.
9. A pharmaceutical product comprising: a. tazobactam or salts
thereof; and b. a ceftolozane composition obtained by lyophilizing
(6R,7R)-3-[5-Amino-4-[3-(2-aminoethyl)ureido]-lmethyl-1H-pyrazol-2-ium-2--
ylmethyl]-7-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(Z)-1-carboxy-lmethyleth-
oxyimino]acetamido]-3-cephem-4-carboxylic acid), wherein the
ceftolozane composition does not contain tazobactam or salts
thereof after lyophilization.
10. The pharmaceutical product of claim 9, wherein the tazobactam
or salt thereof is lyophilized in the absence of ceftolozane.
11. The pharmaceutical product of claim 9, wherein the ceftolozane
in the ceftolozane composition comprises
(6R,7R)-3-[5-Amino-4-[3-(2-aminoethyl)ureido]-1-methyl-1H-pyrazol-2-ium-2-
-ylmethyl]-7-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(Z)-1-carboxy-lmethylet-
hoxyimino]acetamido]-3-cephem-4-carboxylic acid).
12. The pharmaceutical product of claim 9, wherein the ceftolozane
in the ceftolozane composition comprises
(6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazo-
l-2-ium-2-yl)methyl]-7-({(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carb-
oxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-
-2-ene-2-carboxylate.
13. The pharmaceutical product of claim 9, wherein the ceftolozane
composition comprises ceftolozane sulfate.
14. The pharmaceutical product of claim 9, wherein the ceftolozane
composition is obtained by a process comprising freeze-drying an
aqueous solution having a pH of about 5.0 to 7.0 comprising the
ceftolozane without tazobactam.
15. The pharmaceutical product of claim 9, having a pH of about
6.0.
16. The pharmaceutical product of claim 9, wherein about
30.4%-37.2% by weight of the pharmaceutical composition is
ceftolozane sulfate.
17. The pharmaceutical product of claim 16, wherein about
15.2%-18.6% by weight of the pharmaceutical composition is
tazobactam (free acid).
18. The pharmaceutical product of claim 9, comprising ceftolozane
active and tazobactam active in a 2:1 weight ratio.
19. The pharmaceutical product of claim 9, comprising ceftolozane
active and tazobactam active in a molar ratio of 1:0.9 to
0.9:1.0.
20. The pharmaceutical product of claim 9, comprising a total of
1000 mg ceftolozane active and a total of 500 mg tazobactam active
in a unit dosage form.
21. A pharmaceutical composition comprising tazobactam or a salt
thereof, and a lyophilized compound obtained from a solution
without tazobactam, the solution comprising the compound of formula
(I) prior to lyophilization: ##STR00006##
22. The pharmaceutical composition of claim 21, wherein the
tazobactam or salt thereof is lyophilized in the absence of
ceftolozane.
23. The pharmaceutical composition of claim 21, comprising
(6R,7R)-3-[5-Amino-4-[3-(2-aminoethyl)ureido]-lmethyl-1H-pyrazol-2-ium-2--
ylmethyl]-7-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(Z)-1-carboxy-lmethyleth-
oxyimino]acetamido]-3-cephem-4-carboxylic acid).
24. The pharmaceutical composition of claim 21, comprising
(6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazo-
l-2-ium-2-yl)methyl]-7-({(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carb-
oxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-
-2-ene-2-carboxylate.
25. The pharmaceutical composition of claim 21, wherein the
solution is an aqueous solution having a pH of about 5.0 to 7.0
prior to lyophilization.
26. The pharmaceutical composition of claim 21, having a pH of
about 6.0.
27. The pharmaceutical composition of claim 21, wherein about
15.2%-18.6% by weight of the pharmaceutical composition is
tazobactam (free acid).
28. The pharmaceutical composition of claim 21, comprising a total
of 500 mg tazobactam active in a unit dosage form.
29. A pharmaceutical composition comprising a ceftolozane compound
and a tazobactam compound, wherein the pharmaceutical composition
is obtained by a process comprising the steps of: a. forming a
solution comprising a compound of formula (I) without tazobactam
##STR00007## b. obtaining the ceftolozane compound in a powder
ceftolozane composition from the solution of step (a); c. combining
the powder ceftolozane composition with the tazobactam comprising
tazobactam free acid or a salt thereof to form the pharmaceutical
composition.
30. The pharmaceutical composition of claim 29, wherein the
solution is freeze dried to obtain the powder ceftolozane
composition.
31. The pharmaceutical composition of claim 29, wherein the
solution is adjusted to a pH of about 5-7 prior to freeze
drying.
32. The pharmaceutical composition of claim 29, wherein the powder
ceftolozane composition comprises
(6R,7R)-3-[5-Amino-4-[3-(2-aminoethyl)ureido]-lmethyl-1H-pyrazol-2-ium-2--
ylmethyl]-7-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(Z)-1-carboxy-lmethyleth-
oxyimino]acetamido]-3-cephem-4-carboxylic acid).
33. The pharmaceutical composition of claim 29, wherein the powder
ceftolozane composition comprises
(6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazo-
l-2-ium-2-yl)methyl]-7-({(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carb-
oxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-
-2-ene-2-carboxylate.
34. The pharmaceutical composition of claim 29, wherein the
pharmaceutical composition comprises ceftolozane sulfate.
35. The pharmaceutical composition of claim 29, comprising about
30.4%-37.2% by weight ceftolozane active and about 15.2%-18.6% by
weight tazobactam (free acid).
36. The pharmaceutical composition of claim 29, wherein the
tazobactam compound is obtained by lyophilizing tazobactam acidin
the absence of ceftolozane prior to combination of the tazobactam
compound with the powder ceftolozane composition.
37. The pharmaceutical composition of claim 29, comprising
ceftolozane active and tazobactam active in a 2:1 weight ratio.
38. The pharmaceutical composition of claim 29, comprising
ceftolozane active and tazobactam active in a molar ratio of 1:0.9
to 0.9:1.0.
39. The pharmaceutical composition of claim 29, comprising a total
of 1000 mg ceftolozane active and a total of 500 mg tazobactam
active in a unit dosage form.
40. The pharmaceutical composition of claim 9, wherein the
tazobactam is tazobactam sodium.
41. The pharmaceutical composition of claim 21, wherein the
tazobactam is tazobactam sodium.
42. The pharmaceutical composition of claim 29, wherein the
tazobactam is tazobactam sodium.
Description
RELATED APPLICATION
[0001] This application is a continuation of U.S. patent
application Ser. No. 14/214,212, filed Mar. 14, 2013, which claims
priority to U.S. Provisional Patent Application No. 61/792,092,
filed Mar. 15, 2013, and U.S. Provisional Patent Application No.
61/793,007, filed Mar. 15, 2013, both of which are incorporated
herein in their entirety.
TECHNICAL FIELD
[0002] This disclosure relates to antibacterial compositions
comprising ceftolozane and tazobactam.
BACKGROUND
[0003] The pharmaceutical antibiotic composition comprising
ceftolozane and tazobactam in a 2:1 weight ratio of ceftolozane
active to tazobactam active ("CXA-201") displays potent
antibacterial activity, including antibiotic activity against
infections caused by many Gram-negative pathogens such as
Pseudomonas aeruginosa (P. aeruginosa), Escherichia coli (E. coli),
Klebsiella pneumonia (K. pneumonia). In particular, CXA-201 is a
pharmaceutical composition useful for intravenous administration
for the treatment of complicated intra-abdominal infections and/or
complicated urinary tract infections, and is being evaluated for
treatment of pneumonia.
[0004] Ceftolozane is a cephalosporin antibacterial agent, also
referred to as CXA-101, FR264205, or by chemical names such as
(6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazo-
l-2-ium-2-yl)methyl]-7-({(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carb-
oxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-
-2-ene-2-carboxylate, and
713-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimi-
no)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazolio}m-
ethyl-3-cephem-4-carboxylate. The antibacterial activity of
ceftolozane is believed to result from its interaction with
penicillin binding proteins (PBPs) to inhibit the biosynthesis of
the bacterial cell wall which acts to stop bacterial replication.
Ceftolozane sulfate is a pharmaceutically acceptable ceftolozane
salt of formula (I) that can be formulated for intravenous
administration or infusion.
##STR00001##
[0005] In CXA-201, ceftolozane is combined with the
.beta.-lactamase inhibitor ("BLI") tazobactam. Tazobactam is a BLI
against Class A and some Class C .beta.-lactamases, with
well-established in vitro and in vivo efficacy in combination with
active .beta.-lactam antibiotics. Tazobactam can be combined with
ceftolozane as a free acid tazobactam form of formula (II).
##STR00002##
[0006] Pharmaceutical compositions comprising one or more drug
substances can be prepared by lyophilization of a solution
containing the drug substance(s). Lyophilization is a process of
freeze-drying in which water is sublimed from a frozen solution of
one or more solutes. Specific methods of lyophilization are
described in Remington's Pharmaceutical Sciences, Chapter 84, page
1565, Eighteenth Edition, A. R. Gennaro, (Mack Publishing Co.,
Easton, Pa., 1990). It has now been found and reported herein that
compositions formed by lyophilizing ceftolozane and tazobactam
through co-lyophilization, (i.e., the ceftolozane and tazobactam
were combined and lyophilized together in Example 3, as opposed to
separately) resulted in the formation of significant amounts of an
undesired by-product represented by formula (III) (See Example 5
and the results reported in Tables 5 and 6 in FIGS. 7A and 7B).
##STR00003##
[0007] Therefore, there remains a need for compositions comprising
ceftolozane and/or tazobactam with reduced or even undectable
amounts (e.g., less than about 0.03% by high performance liquid
chromatography, or "HPLC") of the compound of formula (III) and
methods for manufacturing these compositions.
SUMMARY
[0008] Applicants have discovered pharmaceutical compositions
comprising ceftolozane and tazobactam with reduced and even
undetectable amounts of the compound of Formula (III), and methods
of manufacturing these compositions. The invention is based in part
on the discovery that the formation of the compound represented by
Formula (III) can be reduced if not completely suppressed by
lyophilizing ceftolozane in the absence of tazobactam and then
blending the lyophilized ceftolozane with a dry tazobactam
composition, such as a tazobactam composition lyophilized in the
absence of ceftolozane (See Example 6 and the results reported in
Tables 8 and 9 in FIGS. 9A and 9B). Based on these results,
pharmaceutical compositions comprising ceftolozane and tazobactam,
and pharmaceutical compositions prepared using ceftolozane and
tazobactam are provided herein. In particular, these pharmaceutical
compositions can include ceftolozane and/or tazobactam with reduced
or even undetectable amounts of a compound of formula (III).
##STR00004##
[0009] In one embodiment, a pharmaceutical composition can include
ceftolozane and tazobactam with less than 0.15%, 0.10%, 0.05% or
0.03% by weight; or from 0.03-0.05%, 0.03-0.1% or 0.03-0.15% by
HPLC or even undectable amounts of the compound of formula (III)
(e.g., less than about 0.03% of the compound of Formula (III)
measured by HPLC). These pharmaceutical compositions can be
obtained by a process comprising the steps of (a) lyophilizing
ceftolozane in the absence of tazobactam to obtain a lyophilized
ceftolozane composition; and (b) combining the lyophilized
ceftolozane with tazobactam under conditions suitable to obtain
said pharmaceutical composition with the aforementioned purity
levels. The combination of the lyophilized ceftolozane composition
with tazobactam can include blending the lyophilized ceftolozane
composition with lyophilized or crystalline tazobactam
material.
[0010] In one aspect, provided herein is a pharmaceutical
composition comprising a blend of separately lyophilized tazobactam
and ceftolozane sulfate in an amount providing 1,000 mg of
ceftolozane active per 500 mg of tazobactam active, further
comprising less than 0.15%, 0.10%, 0.05% or 0.03% by weight; from
0.03-0.05%, 0.03-0.1% or 0.03-0.15% by HPLC; or even undectable
amounts (e.g., less than about 0.03% by HPLC) of a compound of
formula (III) detectable at a retention time relative to
ceftolozane of 1.22 by high performance liquid chromatography
(HPLC) using a Develosil column ODS-UG-5; 5 micrometers;
250.times.4.6 mm, a mobile phase of sodium perchlorate buffer
solution (pH 2.5)/CH.sub.3CN 90:10 (v/v) at a 1.0 mL/min flow rate
and oven temperature of 45.degree. C. (hereinafter referred to as
the "method of Example 2").
[0011] CXA-201 compositions comprising less than about 0.15%,
0.10%, 0.05% or 0.03% by weight; or from 0.03-0.05%, 0.03-0.1% or
0.03-0.15% by HPLC of the compound of formula (III) can be obtained
by a process comprising the steps of: (a) forming a first aqueous
solution comprising ceftolozane (e.g., in a pharmaceutically
acceptable salt such as formula (I)), (b) lyophilizing the first
aqueous solution to obtain a lyophilized ceftolozane composition,
and (c) blending the lyophilized ceftolozane composition with a
tazobactam composition (e.g., tazobactam acid lyophilized in the
absence of ceftolozane) in an amount that provides a 2:1 weight
ratio between the amount of ceftolozane active and tazobactam
active.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIGS. 1A and 1B are chromatograms of CXA-101 ceftolozane
drug substance obtained from the lyophilization process of Example
1 The chromatograms were obtained according to the analytical
method described in Example 2.
[0013] FIG. 2 is a diagram of a lyophilization process for the
ceftolozane obtained according to the process described in Example
1.
[0014] FIG. 3 is a table (Table 1) of peaks for the ceftolozane
prepared by the lyophilization process in Example 1 obtained by
HPLC according to the analytical method of Example 2.
[0015] FIG. 4A is a schematic showing a process for making the
compound of formula (III) with ceftolozane and tazobactam.
[0016] FIG. 4B is a table (Table 2) showing a first composition
that can be lyophilized to form a composition comprising the
compound of formula (III).
[0017] FIG. 5 is a table (Table 3) showing a second composition
that can be lyophilized to form a composition comprising the
compound of formula (III).
[0018] FIG. 6 is a table (Table 4) of the composition of the
formulation used to prepared the Co-Lyophilized Combo drug product
used in Example 5.
[0019] FIG. 7A is a table (Table 5) of the impurity composition of
the Co-Lyophilized Combo drug product at T.sub.0 (time zero),
T.sub.1 (one month) and T.sub.2 (three months) after being
maintained at 25.degree. C./60% relative humidity.
[0020] FIG. 7B is a table (Table 6) of the impurity composition of
the Co-Lyophilized Combo drug product at T.sub.0 (time zero),
T.sub.1 (one month) and T.sub.2 (three months) after being
maintained at 40.degree. C./75% relative humidity.
[0021] FIG. 8 is a table (Table 7) of the composition of the
formulation used to prepare the Blended Combination drug product
used in Example 6.
[0022] FIG. 9A is a table (Table 8) of the impurity composition of
the Blended Combination drug product at T.sub.0 (time zero),
T.sub.1 (one month) and T.sub.2 (three months) after being
maintained at 25.degree. C./60% relative humidity.
[0023] FIG. 9B is a table (Table 9) of the impurity composition of
the Blended Combination drug product at T.sub.0 (time zero),
T.sub.1 (one month) and T.sub.2 (three months) after being
maintained at 40.degree. C./75% relative humidity.
DETAILED DESCRIPTION
[0024] Pharmaceutical compositions comprising ceftolozane and
tazobactam with reduced or even undectable levels of the compound
of formula (III) (e.g., including levels of compound of formula
(III) that are not detectable by HPLC according to Example 2 and/or
comprise less than 0.15%, 0.10%, 0.05% or 0.03% by weight; or from
0.03-0.05%, 0.03-0.1% or 0.03-0.15% by HPLC according to Example 2)
can be obtained by blending a first composition comprising a
therapeutically effective amount of ceftolozane in the absence of
tazobactam with a second composition comprising a therapeutically
effective amount of tazobactam in the absence of ceftolozane to
form a blended pharmaceutical composition.
[0025] The (first) ceftolozane composition can be prepared in the
absence of tazobactam by forming a first aqueous solution
comprising ceftolozane sulfate and other components including
excipients, stabilizers, pH adjusting additives (e.g., buffers) and
the like. Non-limiting examples of these additives include sodium
chloride, citric acid and L-arginine. For example, the use of
sodium chloride results in greater stability; L-arginine is used to
adjust the aqueous solution to a pH of 5-7 (e.g., to pH 6-7) and to
increase the solubility of ceftolozane; and citric acid is used to
prevent discoloration of the product, due to its ability to chelate
metal ions. In one embodiment, the pH of the first aqueous solution
is suitable for making an injectable product (e.g., a pH range of
5-7, including 6-7). Preferably, the first aqueous solution
comprises about 125 mg-500 mg sodium chloride per 1,000 mg of
ceftolozane active. The ceftolozane can be included as an amount of
ceftolozane sulfate of formula (I) containing at least about 1,000
mg ceftolozane active. The (first) aqueous solution is then
lyophilized to form a first lyophilized ceftolozane composition,
which is combined with tazobactam, e.g., the lyophilized tazobactam
(e.g., lyophilized tazobactam sodium) or crystalline tazobactam
[0026] The (second) tazobactam composition can be prepared in the
absence of ceftolozane by forming a second solution comprising
tazobactam. The tazobactam can be included in an amount providing
about 500 mg of tazobactam active per 1,000 mg ceftolozane active
(i.e., a 1:2 weight ratio of tazobactam active to ceftolozane
active). Tazobactam is a .beta.-lactamase inhibitor of the
structure of formula (II) in its free acid form.
##STR00005##
[0027] Unless otherwise indicated, tazobactam can be a free acid, a
sodium salt, an arginine salt, or a hydrate or solvate thereof. In
one embodiment, the tazobactam in the (second) tazobactam
composition is tazobactam acid and the second composition further
comprises sodium bicarbonate or sodium hydroxide. Lyophilizing
tazobactam in the presence of sodium bicarbonate or sodium
hydroxide forms a lyophilized tazobactam sodium, which can then be
further blended with the (first) lyophilized ceftolozane
composition.
[0028] Pharmaceutical compositions with reduced or undectable
amounts of the compound of formula (III) can be obtained by
lyophilizing ceftolozane without formylacetic acid and/or
tazobactam under conditions that prevent formation of the compound
of formula (III) (e.g., Example 1 and 4). The presence of a
compound of formula (III) can be detected by HPLC (e.g., Examples
2, 5 and 6). Specific methods of lyophilization are described in
Example 1 and Remington's Pharmaceutical Sciences, Chapter 84, page
1565, Eighteenth Edition, A. R. Gennaro, (Mack Publishing Co.,
Easton, Pa., 1990). The formation of the compound of formula (III)
can be avoided by preventing the reaction of ceftolozane and
formylacetic acid. In one embodiment, the compound of formula (III)
can be suppressed by separately lyophlizing ceftolozane sulfate and
tazobactam in separate solutions, and then blending the lyophilized
compositions to form a pharmaceutical composition.
[0029] In one aspect, antibiotic pharmaceutical compositions
comprising ceftolozane and tazobactam with less than about 0.15%,
0.10%, 0.05% or 0.03% by weight; or from 0.03-0.05%, 0.03-0.1% or
0.03-0.15% by HPLC of the compound of formula (III) are obtained by
a process comprising the steps of: (a) lyophilizing ceftolozane in
the absence of tazobactam to obtain a lyophilized ceftolozane
composition, and (b) blending the lyophilized ceftolozane
composition with a composition comprising tazobactam under
conditions suitable for attaining the aforementioned purity levels,
e.g., by blending with crystalline tazobactam or lyophilized
tazobactam.
[0030] In another aspect, antibiotic pharmaceutical compositions
comprising ceftolozane and tazobactam and less than about 0.15%,
0.10%, 0.05% or 0.03% by weight; or from 0.03-0.05%, 0.03-0.1% or
0.03-0.15% by HPLC of the compound of formula (III) are obtained by
a process comprising the steps of: (a) lyophilizing tazobactam in
the absence of ceftolozane to obtain a lyophilized tazobactam
composition, and (b) blending the lyophilized tazobactam
composition with a composition comprising ceftolozane (e.g.,
lyophilized ceftolozane sulfate).
[0031] In a third aspect, antibiotic pharmaceutical compositions
comprising ceftolozane and tazobactam and less than about 0.15%,
0.10%, 0.05% or 0.03% by weight; or from 0.03-0.05%, 0.03-0.1% or
0.03-0.15% by HPLC of the compound of formula (III) are obtained by
a process comprising the steps of: (a) lyophilizing tazobactam in
the absence of ceftolozane to obtain a lyophilized tazobactam
composition, (b) lyophilizing ceftolozane in the absence of
tazobactam to obtain a lyophilized ceftolozane composition, and (c)
blending the lyophilized tazobactam composition with the
lyophilized ceftolozane composition.
[0032] Pharmaceutical compositions comprising the compound of
formula (III), ceftolozane and tazobactam can be formulated to
treat infections by parenteral administration (including
subcutaneous, intramuscular, and intravenous) administration.
Pharmaceutical compositions may additionally comprise excipients,
stabilizers, pH adjusting additives (e.g., buffers) and the like.
Non-limiting examples of these additives include sodium chloride,
citric acid and L-arginine. For example, the use of sodium chloride
results in greater stability; L-arginine is used to adjust pH and
to increase the solubility of ceftolozane; and citric acid is used
to prevent discoloration of the product, due to its ability to
chelate metal ions. In one particular embodiment, the
pharmaceutical compositions described herein are formulated for
administration by intravenous injection or infusion.
[0033] Other pharmaceutical antibiotic compositions can include
ceftolozane sulfate and the compound of formula (III). For example,
pharmaceutical compositions comprising 0.13%, 0.15%, 0.30%, 0.38%,
0.74% or 0.97% of the compound of formula (III) are herein. The
pharmaceutical antibiotic compositions can be provided in a unit
dosage form (e.g., in a vial). The unit dosage form can be
dissolved with a pharmaceutically acceptable carrier, and then
intravenously administered. The unit dosage form comprises 1000 mg
of ceftolozane active and 500 mg tazobactam, typically 1000 mg
ceftolozane active as ceftolozane sulfate and 500 mg of tazobactam
active as tazobactam sodium, argininate or free acid. The unit
dosage forms are commonly stored in vials.
[0034] In one aspect, provided herein is a unit dosage form
container (e.g., a bag, vial or the like) containing a unit dosage
form of a pharmaceutical composition formulated for parenteral
administration for the treatment of complicated intra-abdominal
infections or complicated urinary tract infections, the
pharmaceutical composition comprising a therapeutically effective
amount of ceftolozane sulfate and tazobactam in a ratio of 1,000 mg
ceftolozane active per 500 mg of tazobactam active, the
pharmaceutical composition obtained by a process comprising the
steps of: [0035] a. lyophilizing a first aqueous solution in the
absence of tazobactam, the first aqueous solution comprising
ceftolozane sulfate, 125 mg to 500 mg of sodium chloride per 1,000
mg of ceftolozane active, L-arginine and/or citric acid in an
amount effective to adjust the pH of the first aqueous solution to
5-7 (e.g., 6-7) prior to lyophilization to obtain a first
lyophilized ceftolozane composition, [0036] b. lyophilizing a
second solution in the absence of ceftolozane, the second solution
comprising tazobactam being lyophilized to form a second
lyophilized tazobactam composition; and [0037] c. blending the
first lyophilized ceftolozane composition and the second
lyophilized tazobactam composition to obtain a blended
pharmaceutical composition in the unit dosage form.
[0038] In one embodiment of the unit dosage form container, the
tazobactam in the second solution is tazobactam acid, and wherein
the tazobactam acid in the second solution is lyophilized in the
presence of sodium bicarbonate or sodium hydroxide, thereby forming
lyophilized tazobactam sodium in the second lyophilized tazobactam
solution.
[0039] A pharmaceutical composition can include ceftolozane sulfate
and tazobactam in an amount providing 1,000 mg of ceftolozane
active per 500 mg of tazobactam active, and 0.03% to 0.15% by HPLC
of a compound of formula (III) detectable at a retention time
relative to ceftolozane of 1.22 by high performance liquid
chromatography using a Develosil column ODS-UG-5; 5 micrometers;
250.times.4.6 mm, a mobile phase of sodium perchlorate buffer
solution (pH 2.5)/CH.sub.3CN 90:10 (v/v) at a 1.0 mL/min flow rate
and oven temperature of 45.degree. C. Optionally, the
pharmaceutical composition can further include 125 mg to 500 mg of
sodium chloride per 1,000 mg of ceftolozane active, and L-arginine.
The tazobactam in the composition can be tazobactam sodium.
[0040] The pharmaceutical compositions provided herein comprising
ceftolozane sulfate and tazobactam in a ratio of 1,000 mg
ceftolozane active per 500 mg of tazobactam active, can be obtained
by a process comprising the steps of: [0041] a. lyophilizing a
first aqueous solution in the absence of tazobactam, the first
aqueous solution comprising ceftolozane sulfate at a pH of 5-7
(e.g, 6-7) prior to lyophilization to obtain a first lyophilized
ceftolozane composition, [0042] b. blending the first lyophilized
ceftolozane composition with tazobactam to obtain an antibacterial
composition.
[0043] The pharmaceutical compositions can be administered for the
treatment of infections, such as complicated intra-abdominal
infections, complicated urinary tract infections (cUTIs) and
pneumonia (e.g., community-acquired, hospital-acquired, etc). In
one aspect, provided herein is a method for the treatment of
bacterial infections in a mammal, comprising administering to said
mammal a therapeutically effective amount of a pharmaceutical
composition prepared according to the methods described herein. In
one aspect, provided herein is a method for the treatment of
bacterial infections in a mammal, comprising administering to said
mammal a therapeutically effective amount of a pharmaceutical
composition prepared according to the methods described herein. A
method for the treatment of bacterial infections in a mammal can
comprise administering to said mammal a therapeutically effective
amount of a pharmaceutical composition comprising ceftolozane
sulfate and sodium chloride. Non-limiting examples of bacterial
infections that can be treated by the methods of the invention
include infections caused by: aerobic and facultative gram-positive
microorganisms (e.g., Staphylococcus aureus, Enterococcus faecalis,
Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus
pneumonia, Streptococcus pyogenes, Viridans group streptococci),
aerobic and facultative gram-negative microorganisms (e.g.,
Acinetobacter baumanii, Escherichia coli, Haemophilus influenza,
Klebsiella pneumonia, Pseudomonas aeruginosa, Citrobacter koseri,
Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae,
Proteus mirabilis, Proteus vulgaris, Serratia marcescens,
Providencia stuartii, Providencia rettgeri, Salmonella enterica),
gram-positive anaerobes (Clostridium perfringens), and
gram-negative anaerobes (e.g., Bacteroides fragilis group (e.g., B.
fragilis, B. ovatus, B. thetaiotaomicron, and B. vulgates),
Bacteroides distasonis, Prevotella melaminogenica). In certain
embodiments of the methods described herein, bacterial infection is
associated with one or more of the following conditions:
complicated intra-abdominal infections, complicated urinary tract
infections (cUTIs) and pneumonia (e.g., community-acquired, or
nosocomial pneumonia). Community-acquired pneumonia (moderate
severity only) can include infections caused by
piperacillin-resistant, beta-lactamase producing strains of
Haemophilus influenza. Nosocomial pneumonia (moderate to severe)
caused by piperacillin-resistant, beta-lactamase producing strains
of Staphylococcus aureus and by Acinetobacter baumanii, Haemophilus
influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
[0044] As used herein, "treating", "treat" or "treatment" describes
the management and care of a patient for the purpose of combating a
disease, condition, or disorder and includes the administration of
a pharmaceutical composition of the present invention to alleviate
the symptoms or complications of a disease, condition or disorder,
or to reduce the extent of the disease, condition or disorder. The
term "treat" can also include treatment of a cell in vitro or an
animal model.
[0045] By a "therapeutically effective amount" of a compound of the
invention is meant a sufficient amount of the compound to treat the
disorder (e.g., bacterial infection). The specific therapeutically
effective amount that is required for the treatment of any
particular patient or organism (e.g., a mammal) will depend upon a
variety of factors including the disorder being treated and the
severity of the disorder; the activity of the specific compound or
composition employed; the specific composition employed; the age,
body weight, general health, sex and diet of the patient; the time
of administration, route of administration, and rate of excretion
of the specific compound employed; the duration of the treatment;
drugs used in combination or coincidental with the specific
compound employed; and like factors well known in the medical arts
(see, for example, Goodman and Gilman's, "The Pharmacological Basis
of Therapeutics", Tenth Edition, A. Gilman, J. Hardman and L.
Limbird, eds., McGraw-Hill Press, 155-173, 2001, which is
incorporated herein by reference in its entirety). The
therapeutically effective amount for a given situation can be
readily determined by routine experimentation and is within the
skill and judgment of the ordinary clinician.
[0046] As used herein, the term "ceftolozane active" refers to the
active portion of a salt form of ceftolozane in the free base form
of ceftolozane.
[0047] As used herein, the term "tazobactam active" refers to the
active portion of a salt form of tazobactam in the tazobactam free
acid form.
[0048] As used herein, "1,000 mg of ceftolozane as ceftolozane
active" refers to an amount of ceftolozane sulfate effective to
provide 1,000 mg of ceftolozane active. The amount of sodium
chloride per gram of ceftolozane activity in a pharmaceutical
composition containing ceftolozane sulfate and sodium chloride can
be calculated using the relevant molecular weights of ceftolozane,
ceftolozane sulfate, sodium chloride and sodium. As used herein,
"500 mg of tazobactam as tazobactam active" refers to an amount of
tazobactam sodium or tazbactam arginine effective to provide 500 mg
of tazobactam active.
[0049] As used herein, references to an amount of a substance as "%
of the compound of . . . " or "% by HPLC" (unless otherwise
indicated) refer to the % of a compound detected by high
performance liquid chromatography (HPLC) according to the method of
Example 2.
Illustrative Examples of Selected Embodiments of the Invention
Example 1
Manufacturing Procedure of Bulk (Tray) Lyophilized Ceftolozane
[0050] There are four main steps in the manufacture of CXA-101 bulk
drug product: dissolution, sterile filtration, bulk lyophilization,
and packaging into Sterbags.RTM.. These four main steps are
composed of a total of 20 minor steps. The CXA-101 bulk drug
product manufacturing process is presented below.
I. Dissolution
[0051] 1. The prescribed amount of water for injection ("WFI") is
charged into the dissolution reactor.
[0052] 2. A prescribed amount of citric acid is added.
[0053] 3. The solution is cooled at 5.degree. C. to 10.degree.
C.
[0054] 4. A prescribed amount of CXA-101 drug substance is added to
the solution.
[0055] 5. A prescribed amount of L-arginine is slowly added to the
solution.
[0056] 6. A check for complete dissolution is performed. Solution
pH is verified to be in the target range of 6.5 to 7.0.
[0057] 7. A prescribed amount of sodium chloride is added to the
solution.
[0058] 8. A check for complete dissolution is performed. Solution
pH is verified to be in the target range of 6.0 to 7.0. If the pH
is out of this range adjust with either L-Arginine or citric
acid.
[0059] 9. WFI is added to bring the net weight to 124.4 kg and the
solution is mixed well.
[0060] 10. Samples are withdrawn for testing of final pH.
II. Sterile Filtration
[0061] 11. The solution is passed through the filter (pore size
0.45 .mu.m) followed by double filters (pore size 0.22 .mu.m) onto
a shelf on the Criofarma lyophilizer.
[0062] 12. The line is washed with WFI.
[0063] 13. The washing solution is passed from Step 12 through
sterile filtration.
III. Bulk Lyophilization
[0064] 14. The washing solution is loaded onto a separate shelf in
the lyophilizer (and later discarded).
[0065] 15. The solution is lyophilized until dry.
[0066] 16. The product shelf is cooled to 20.degree.
C..+-.5.degree. C.
IV. Packaging into Sterbags.RTM.
[0067] 17. The lyophilized bulk drug product powder is milled.
[0068] 18. The milled powder is sieved.
[0069] 19. The sieved powder is blended for 30 minutes.
[0070] 20. The powder is then discharged into Sterbags.RTM.
Prefiltration and Sterile-Filtration
[0071] Filtrate the compounded solution with a sterile tilter-set
which consists of a 0.2 um polyvinylidene fluoride membrane filter
(Durapore.RTM., Millipore) and a 0.1 urn polyvinylidene fluoride
membrane filter (Durapore.RTM., Millipore) connected in tandem.
Confirm the integrity of each filter before and after the
filtration. Take approximately 100 mL of the filtrate in order to
check bioburden.
[0072] Filter the prefiltered compounded solution through a sterile
filter-set which consists of a 0.2 um polyvinylidene fluoride
membrane filter and a 0.1 um polyvinylidene fluoride membrane
filter connected in tandem, and introduce the final filtrate into
an aseptic room. Confirm the integrity of each filter before and
after the filtration.
Processing of Vial, Stopper and Flip-Off Cap
[0073] Wash a sufficient quantity of 28 mL vials with water for
injection and sterilize the washed vials by a dry-heat sterilizer.
Then transfer the sterilized vials into a Grade A area located in
an aseptic room.
[0074] Wash a sufficient quantity of stoppers with, water for
injection. Sterilize and dry the washed stoppers by steam
sterilizer. Then transfer the sterilized stoppers into a Grade A
area located in an aseptic room.
[0075] Sterilize a sufficient quantity of flip-off caps by steam
sterilizer. Then transfer the sterilized flip-off caps into a Grade
A or B area located in an aseptic room.
Filling and Partially Stoppering
[0076] Adjust the fill weight of the filtered compounded solution
to 11.37 g (corresponds to 10 mL of the compounded solution), then
start filling operation. Check the filled weight in sufficient
frequency and confirm it is in target range (11.37 g.+-.1%, 11.26
to 11.43 g). When deviation from the control range (11.37 g.+-.2%,
11.14 to 11.59 g) is occurred, re-adjust the filling weight.
[0077] Immediately after a vial is filled, partially stopper the
vial with a sterilized stopper. Load the filled and partially
stoppered vials onto the shelves of a lyophilizer aseptically.
Lyophilization to Crimping, Visual Inspection, Labeling and
Packaging
[0078] After all filled and partially stoppered vials are loaded
into a lyophilizer, start the lyophilization program shown in FIG.
2. Freeze the loaded vials at -40.degree. C. and keep until all
vials freeze. Forward the program to primary drying step (shelf
temperature; -20.degree. C., chamber pressure; 100 to 150 mTorr).
Primary drying time should be determined by monitoring the product
temperature. Forward the program to secondary drying step (shelf
temperature; 30.degree. C., chamber pressure; not more than 10
mTorr) after completion of the primary drying step. After all vials
are dried completely, return the chamber pressure to atmospheric
pressure with sterilized nitrogen. Then stopper vials
completely.
[0079] Unload the lyophilized vials from the chamber and crimp with
sterilized flip-off caps.
[0080] Subject all crimped vials to visual inspection and label and
package all passed vials.
Example 2
Analytical HPLC Method
A, Operative Conditions
Column Develosil ODS-UG-5; 5 .mu.m, 250.times.4.6 mm (Nomura
Chemical, Japan)
[0081] Mobile phase Sodium Perchlorate Buffer Solution (PH
2.5)/CH.sub.3CN 90:10 (v/v) Flow rate 1.0 mL/min
Wavelength 254 nm
[0082] Injection volume 10 .mu.L
Oven Temperature 45.degree. C.
[0083] Run Time 85 minutes
Gradient Profile:
TABLE-US-00001 [0084] Time (min) A % B % 0 75 25 30 70 30 60 0 100
85 0 100 85.1 75 25 110 75 25
B. Mobile Phase Preparation.
[0085] Sodium Perchlorate Buffer Solution was made by dissolving
14.05 g of sodium perchlorate Monohydrate in 1000.0 mL of water
followed by adjusting pH to 2.5 with diluted perchloric acid (1 in
20).
[0086] Mobile Phase was then made by mixing Sodium Perchlorate
Buffer Solution (pH 2.5) and acetonitrile in the ratio 90:10
(v/v).
[0087] Sodium Acetate Buffer Solution pH 5.5 (Diluent) was made by
dissolving 1.36 g of sodium acetate trihydrate in 1000.0 mL of
water followed by adjusting to pH 5.5 with diluted acetic acid (1
in 10).
C. Sample Preparation.
[0088] Sample solution: dissolve 20.0 mg, exactly weighed, of
Sample, in 20.0 mL of water (Prepare just before injection into
HPLC system).
[0089] System Suitability Solution (1%): take 1.0 mL of the Sample
Solution (use first sample if more are present) and transfer into a
100.0 mL volumetric flask, dilute with water to volume and mix.
HPLC Analysis Procedure
[0090] 1. Inject Blank (water) 2. Inject System Suitability
Solution and check for tailing factor and theoretical plate number
for CXA-101 peak: [0091] The tailing factor must not be greater
than 1.5 [0092] Theoretical plates number must not be less than
10000
3. Inject Sample Solution
[0093] 4. Inject System Suitability Solution and check for tailing
factor and theoretical plate number for CXA-101 peak. [0094] The
tailing factor must not be greater than 1.5 [0095] Theoretical
plates number must not be less than 10000 5. Identify the peaks of
Related Substances in the Sample chromatogram based on the
reference chromatogram reported in FIGS. 1A and 1B or,
alternatively, on the basis of the RRT values reported in Table 1
(FIG. 3)
E. Calculations
[0096] I. Report for each related substance its amount as expressed
by area percent.
C i = A i .times. 100 A t + A i ##EQU00001##
[0097] wherein:
[0098] C.sub.i=Amount of related substance i in the Sample, area
%
[0099] A.sub.i=Peak area of related substance i in the Sample
chromatogram
[0100] A.sub.t=Area of CXA-101 peak in the Sample chromatogram
[0101] A.sub.t+.epsilon.A.sub.i=Total peaks area in the Sample
chromatogram
[0102] Consider as any Unspecified Impurity, each peak in the
chromatogram except CXA-101, peaks from 1 to 11 and every peak
present in the blank chromatogram and report the largest.
II. Report the total impurities content as expressed by the
following formula:
C T = A i .times. 100 A t + A i ##EQU00002##
[0103] wherein:
[0104] C.sub.T=total impurities content in the Sample, area %
[0105] A.sub.r=area of CXA-101 peak in the sample chromatogram
[0106] .epsilon.A.sub.i=total peak areas of impurities in the
sample chromatogram
Example 3
Manufacturing of Combination Product (Tazobactam and Ceftolozane)
Comprising a Compound of Formula (III) by Co-Lyophilization
[0107] Compositions comprising the compound of formula (III) were
prepared by the process shown in FIG. 4A by (a) forming an aqueous
solution comprising the components in Table 1 (FIG. 4B), and (b)
lyophilizing the aqueous solution. Sodium content was approximately
78 mg/g of tazobactam in drug product after lyophilization. Water
was removed during the lyophilization process and is controlled at
no more than 4% by HPLC.
Example 4
Manufacturing of Combination Product (Tazobactam and CXA-101)
without HPLC-Detectable Amounts of the Compound of Formula (III) by
Blending
Sterile Dry Blending of Bulk Lyophilized Ceftolozane and Bulk
Lyophilized Tazobactam
[0108] The CXA-101 produced by Example 1 is blended with
lyophilized tazobactam. A low energy drum blender that agitates the
material by tumbling and also moving the bed up and down is used. A
representative process of blending is described according to the
table in FIG. 5. The table in FIG. 5 shows in-process testing of
blending samples of bulk drug product at five places. For
CXA-101/tazobactam for injection, the blender was charged with 23.4
kg of CXA-101 bulk product, and 5.4 kg of tazobactam bulk product.
Both the CXA-101 and tazobactam were individually lyophilized
beforehand. The material was blended for 180 minutes. In-process
tests of content assay for both CXA-101 and tazobactam were
performed to assess the homogeneity using the samples of blend
materials taken from three places. The RSD for each of CXA-101 and
tazobactam content assay was no greater than 2% and the RSD for the
ratio of CXA-101/tazobactam was no greater than 2%. (See Table 3 in
FIG. 5).
Example 5
Co-Lyophilization of Ceftolozane and Tazobactam Produces the
Compound of Formula (III) (RRT 1.22)
[0109] The Co-Lyophilized Combo Drug Product was prepared as
described above in Example 3. The formulation composition of the
Co-Lyophilized Combo drug product is shown in FIG. 6 (Table 4).
This sample was maintained at 25.degree. C./RH=60% and 40.degree.
C./RH=75% after one month (T1) and three months (T2). Samples were
analyzed using a HPLC method as described in Example 2. The data
for analysis of the samples by HPLC is shown in the tables in FIG.
7A (Table 5: Stability data of Co-Lyo Combo Drug Product at
25.degree. C.) and FIG. 7B (Table 6: Stability data Co-Lyo Combo
Drug Product at 40.degree. C.). The presence of the compound of
Formula (III) was identified has having a retention time of about
1.22 as measured by HPLC (see Example 2). RRT=1.22 was observed in
co-lyophilized drug product. The compound of formula (III) is
believed to be formed by a reaction between ceftolozane and
formylacetic acid, which was a degradation product of tazobactam.
The amount of the compound of formula (III) in a composition
comprising ceftolozane and tazobactam can be increased over time at
25.degree. C. and at 40.degree. C.
Example 6
Assessment of Blend Combination Drug Product
A. Preparation of Blend Combination Drug Product
[0110] The blend drug product was prepared, as described above in
Example 4, on lab scale by use of a small blender. The composition
of the blend drug product is shown in Table 7, FIG. 8. The CXA-101
was obtained by lyophilization of ceftolozane sulfate in the
absence of tazobactam, and the tazobactam sodium material was
obtained by lyophilization of tazobactam prior to blending of the
ceftolozane and tazobactam components.
B. Stress Test
[0111] This sample was put into stability study. The following
Tables 8 (FIG. 9A) and 9 (FIG. 9B) are representative examples that
summarizes the results at 25.degree. C./RH=60% and 40.degree.
C./RH=75% after one month (T1) and three months (T2). Samples were
analyzed using a HPLC method as described in Example 7.
C. Conclusion
[0112] The data at both 25.degree. C. and at 40.degree. C. have
shown that the blending process inhibits formation of amounts of
the impurity RRT=1.22 to below the detection limit of the HPLC
method of Example 2.
Example 7
Stability Study
[0113] A stability study of Combo Drug Product for Injection bulk
drug product was carried out at long term storage conditions (e.g.,
25.degree. C./60% RH), in accordance with ICH guidelines. This
formal stability study examined the effect of temperature and
humidity on CXA-101/tazobactam for Injection bulk drug product
stability when stored in the container closure configuration of
Sterbag.RTM..
[0114] A stability study of Combo Drug Product for Injection
finished drug product was carried out at long term storage
conditions (e.g., 25.degree. C., 60% RH), and an accelerated
stability condition (e.g., 40.degree. C./75% RH), in accordance
with ICH guidelines. This formal stability study examined the
effect of temperature and humidity on CXA-101/tazobactam product
stability in the container closure configuration of the finish
product vial.
Example 8
Preferred Pharmaceutical Composition Comprising Ceftolozane and
Tazobactam
[0115] Pharmaceutical compositions comprising ceftolozane and
tazobactam with less than 0.15% (measured by HPLC according to
Example 2) of the compound of formula (III) can be obtained as
described herein.
TABLE-US-00002 TABLE 10 Excipients Used in Ceftolozane composition
Inactive Concentration Ingredients Amount, in Infusion Rationale
for Database Component Function mg/Vial Solution, % Inclusion (IID)
Range Citric acid Chelating 21 0.02 Used to prevent 0.0025 to 50%
agent discoloration and degradation Sodium Stabilizing 487 0.49
Used as a stabilizing 0.187 to 45% Chloride agent agent for
ceftolozane sulfate L-arginine Alkalizing 600.sup.i) 0.60 Used to
adjust 0.29 to 88% agent Q.S. for pH ceftolozane solution
adjustment pH .sup.i)L-arginine is added as needed to achieve pH
6.5 .+-. 0.5; 600 mg per vial is considered a representative total
amount.
TABLE-US-00003 TABLE 11 Unit Compositions of Ceftolozane/Tazobactam
for Injection, 1000 mg/500 mg Nominal Composition Component
Function mg per Vial Ceftolozane Ceftolozane Active 1147
composition.sup.1) Sulfate Citric Acid, Chelating 21 Anhydrous
Agent Sodium Stabilizing 487 Chloride Agent L-Arginine Alkalizing
600.sup.2) Agent Q.S. for pH adjustment Tazobactam Sodium.sup.3)
Active 537 Nitrogen Processing Q.S. Aid.sup.ii) Total Weight 2792
.sup.1)Actual amount of ceftolozane composition will vary based on
the measured potency. Ceftolozane sulfate, 1147 mg, corresponds to
1000 mg ceftolozane free base. .sup.2)L-arginine is added as needed
to achieve pH 6.5 .+-. 0.5; 600 mg per vial is considered a
representative total amount. .sup.3)Actual weight of tazobactam
sodium will vary based on the measured potency. Tazobactam sodium
537 mg, corresponds to 500 mg tazobactam free acid 4) Nitrogen
blanket is applied after powders are dispensed to the vial and
prior to insertion of stopper.
[0116] A first aqueous solution comprising the ingredients in the
Ceftolozane Drug Composition ("Composition") in Table 11 is
lyophilized in the absence of tazobactam to provide the Ceftolozane
Composition lyophilized composition. The first aqueous solution
comprises ceftolozane sulfate and the specific excipients in the
preferred compositions, in an amount per unit dosage form provided
by the quantities and functions as provided in Table 10. All
excipients are compendial and typical for sterile pharmaceutical
dosage forms, requiring no additional treatment prior to use in the
formulation. The excipients are used in levels within the range
established in other FDA approved products as described in the
Inactive Ingredients Database (IID). A second solution comprising
tazobactam acid and sodium bicarbonate is lyophilized in the
absence of ceftolozane to obtain the Tazobactam Sodium Composition
in Table 11. Subsequently, the lyophilized Tazobactam Sodium
Composition is dry blended with the Ceftolozane Composition
lyophilized composition comprising tazobactam sodium and
ceftolozane sulfate in a weight ratio providing 500 mg of
tazobactam acid equivalent per 1,000 mg of ceftolozane active
equivalent.
* * * * *